SIGHT.PA
Price:
$0.3055
Market Cap:
$37.99M
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage t...[Read more]
Industry
Biotechnology
IPO Date
2016-07-13
Stock Exchange
EURONEXT
Ticker
SIGHT.PA
According to GenSight Biologics S.A.’s latest financial reports and current stock price. The company's current ROE is 72.45%. This represents a change of 28.86% compared to the average of 56.23% of the last 4 quarters.
The mean historical ROE of GenSight Biologics S.A. over the last ten years is -80.07%. The current 72.45% ROE has changed -190.49% with respect to the historical average. Over the past ten years (40 quarters), SIGHT.PA's ROE was at its highest in in the June 2020 quarter at 3.11%. The ROE was at its lowest in in the June 2022 quarter at -334.50%.
Average
-80.07%
Median
-54.81%
Minimum
-291.56%
Maximum
180.80%
Discovering the peaks and valleys of GenSight Biologics S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 287.22%
Maximum Annual ROE = 180.80%
Minimum Annual Increase = -201.02%
Minimum Annual ROE = -291.56%
Year | ROE | Change |
---|---|---|
2023 | 85.50% | -52.71% |
2022 | 180.80% | -201.02% |
2021 | -178.97% | -38.62% |
2020 | -291.56% | 11.52% |
2019 | -261.45% | 86.56% |
2018 | -140.15% | 219.65% |
2017 | -43.84% | 5.91% |
2016 | -41.40% | -11.08% |
2015 | -46.56% | -26.17% |
2014 | -63.06% | 287.22% |
The current ROE of GenSight Biologics S.A. (SIGHT.PA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
29.11%
5-year avg
-93.14%
10-year avg
-80.07%
GenSight Biologics S.A.’s ROE is greater than DBV Technologies S.A. (-104.46%), less than Inventiva S.A. (325.27%), less than Quantum Genomics SA (1.40%), greater than ABIVAX SA (-110.04%), less than Nanobiotix S.A. (283.43%),
Company | ROE | Market cap |
---|---|---|
-104.46% | $81.53M | |
325.27% | $216.28M | |
1.40% | $5.00M | |
-110.04% | $401.67M | |
283.43% | $181.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GenSight Biologics S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GenSight Biologics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is GenSight Biologics S.A.'s ROE?
How is the ROE calculated for GenSight Biologics S.A. (SIGHT.PA)?
What is the highest ROE for GenSight Biologics S.A. (SIGHT.PA)?
What is the 3-year average ROE for GenSight Biologics S.A. (SIGHT.PA)?
What is the 5-year average ROE for GenSight Biologics S.A. (SIGHT.PA)?
How does the current ROE for GenSight Biologics S.A. (SIGHT.PA) compare to its historical average?